Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
VALPROATE SODIUM
Desitin Arzneimittel GmbH
Solution for Injection
2000-12-08
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Orfiril 100 mg/ml Solution for Intravenous Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium valproate 100 mg/ml For excipients, see 6.1 3 PHARMACEUTICAL FORM Solution for injection. Clear colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Orfiril injection solution should be used for epileptic patients for whom oral therapy with sodium valproate is not possible. Primarily generalised epileptic seizures such as absence attacks (petit mal, absence), myoclonic and tonic-clonic seizures. Sodium valproate may also be used either alone or in combination with other antiepileptic medicinal products in other seizure type’s e.g. simple or multiform partial seizures or secondarily generalised partial seizures. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Orfiril 100 mg/ml solution for injection is intended exclusively for intravenous administration. The dosage should be determined according to age and weight and monitored individually by the physician on the basis of concentration determinations.Close monitoring of plasma levels and - if necessary - dosage adjustments have to be performed during the change-over to a parenteral therapy, during the parenteral therapy and during the switch back to oral therapy, in particular in such patients receiving higher doses of valproate or in patients receiving medicinal products potentially influencing the metabolism of valproate. Therapeutic efficacy is usually reached at plasma levels between 50 and 100 mg/L (340-700 µmol/L).The mean daily dosages during maintenance treatment are as follows: Children: 30 mg sodium valproate/kg body weight Adolescents: 25 mg sodium valproate/kg body weight Adults: 20 mg sodium valproate/kg body weight Higher maintenance doses fo Read the complete document